BFRI – biofrontera inc. (US:NASDAQ)
Stock Stats
News
Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT [Yahoo! Finance]
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT
Biofrontera (NASDAQ:BFRI) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Biofrontera Inc. (BFRI) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Form 8-K Biofrontera Inc. For: Nov 13
Form 10-Q Biofrontera Inc. For: Sep 30
Form SCHEDULE 13G/A Biofrontera Inc. Filed by: Rosalind Advisors, Inc.
Form 8-K Biofrontera Inc. For: Nov 04
Form 8-K Biofrontera Inc. For: Nov 06
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.